
€7.34m for cancer vaccine developer
Private clinical-stage biotech MaxiVAX announced that it has been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020 EIC...

Creoptix AG closes CHF8m financing round
The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors....

Pierre Fabre amends license agreement with Puma Biotechnology
According the extended agreement, Pierre Fabre may not only market the breast cancer recurrence blocker Nerlynx® (neratinib) within Europe and...

New malaria lead kills 99.9% of pathogens
The researchers built on the fact, that Plasmodium is highly dependent on external supply and metabolisation of vitamin B 5 (pantothenamide). They...

Abcam buys Expedeon’s immunology business
“This purchase price is equivalent to twice Expedeon’s current market capitalisation or excess of 9-times 2018 annual group revenue,” the company...

Successful EFIB in Brussels
More than 260 companies with 480 delegates from 30 countries joined for this year’s “European Forum for industrial Biotechnology and Bioeconomy”...

MS: Polpharma joins forces with Sandoz
Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is a...